The role of Lp(a) and oxPLs in atherosclerosis
We are delighted to welcome Prof Sotirios (Sam) TSIMIKAS to the HEART UK conference on 7 July to present current and future therapeutic agents and interventions targeting Lp(a) and oxPLs.
Dr. Tsimikas is Professor of Medicine and the Director of Vascular Medicine at the University of California San Diego School of Medicine. His education and training included obtaining his MD degree from the University of Massachusetts Medical School, Internal Medicine training at the University of Massachusetts Medical Center, and separate fellowships in Cardiovascular Medicine, Atherosclerosis and Molecular Medicine and Interventional Cardiology at the University of California San Diego (UCSD( Medical Center. Dr. Tsimikas is the Founding Director of the Vascular Medicine Program withing the Cardiovascular Medicine Division, which encompasses treating patients in the continuum of high-risk primary prevention to endovascular intervention.
Find out more on our HEART UK conference programme on the HCP pages. The Health Professional area of the website is intended only for healthcare professionals.
This event is intended for healthcare professionals from the UK and receives sponsorship from pharmaceutical companies
Related stories
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023
- New SNOMED Codes for FH DNA test results!
- Healthcare Professional Dietary Survey Prize Draw 2022
- Opportunity to join the NICE CG181 guideline committee
- NICE launches review of methods and processes for health technology evaluation
- The Essential Cholesterol Programme for Primary Care
- Add on to take back control. Do we have the solutions to the gaps in our lipid treatment pathway?
- Familial Hypercholesterolaemia: from Epidemiology to Genetics – a paradigm shift?